The standout talk for me at ATTD2024 was by Doctor Dessi Zaharieva on making exercise guidelines practical. It was standout for a couple of reasons. Firstly, it was a great talk, accessible to people of all academic levels and secondly, it was practical: the guidelines presented can be used by people with type 1 diabetes easily and without a pocket calculator/slide rule (am I aging myself with that reference?) on hand.

You may also recall that, back in November, I did a post on a talk by John Pemberton at ISPAD2023 (also mentioning Dessi) on the same topic.

This blog will look to bring together the two talks (and my own experiences running the Blue Circle Cycle Club) so others can use the knowledge and, hopefully, it will encourage them to incorporate exercise into their type 1 management routine. The focus will be on bike riding but feel free to follow the links for tips on other forms of exercise.

What Did John (and Dessi) Say at ISPAD 2023? A Recap of my Previous Post

In my previous post, I had the following key points:

• Exercise, as it increases your heart rate, makes insulin stronger and last longer as it gets to circulate around the body more before it is broken down by the liver and kidneys
• Aerobic exercise tends to lower blood sugar levels which, combined with the ‘amplified insulin’ can make hypoglycemia more likely
• Exercise has many benefits and Dessi expresses it really well in just one slide

• A Continuous Glucose Monitor (CGM) is really useful when exercising as it gives you near-real time feedback on your blood sugar levels, allowing you to address any hypos before they become an issue. For people not using CGMs, Hypoactive suggests “test your blood glucose (BGL) at least twice, 15-30 minutes apart before you exercise.” to understand the direction you are trending and regularly test during exercise.
• Non-Looping Food Strategy: Eat before exercise to bring you up to around 7-10mmol/L (126-180mg/dL) to act as a buffer against going low
• Non-Looping Insulin Strategy: Reduce basal insulin by 20% leading up to exercise, adjust in subsequent rides if too high/low
• Looping Food Strategy: None. Cannot eat to raise BGLs as the loop will counter it, unless you deactivate the loop and follow the MDI/Non-Looping strategy
• Looping Insulin Strategy: Raise BGL target level to, say, 8mmol/L (144mg/dL) and set system to ‘exercise mode’ if available when exercising
• Roughly speaking, if you are at your target level when exercising, take around 15g of carbohydrates every 20 minutes to maintain it. If you are above but dropping fast, take the same, if you are below and heading upwards take the same and if you are below and flat or heading downwards, take more than 15g of carbohydrate per 20 minutes
• Hypoactive suggests monitoring glucose levels for at least 24 hours after exercise and Diatribe recommends reducing bolus insulin by 50% for meals or snacks up to two hours after exercise.

What is Dessi Saying at ATTD2024?

Dessi, via Dana Lewis, generously gave me a copy of her slides so I have much clearer images for this blog than my original tweets.

I will focus on presenting the ‘practical’ slides than give the full presentation.

Starting Glucose

Bike riding is considered a Low-Moderate Intensity exercise so the suggestion is to start between 7-14mmol/L (126-252 mg/dL) which is in broad agreement with the previous advice.

Mealtime Insulin Before Exercise

In my previous blog, Diatribe had suggested reducing bolus injections by up to 50% leading up to exercise and we see here this is in broad agreement, especially with Low-Moderate exercise.

Basal Insulin Before Exercise

For non-loopers, John’s position was to reduce basal insulin by about 20% before exercise. Arguably Dessi’s position is not as strong saying a 10-20% reduction is only needed if the day is unusually active but, with John’s suggestion to adjust based on experience, we can see there is a middle ground between the two positions.

Snacks During Exercise (CGM)

Again, we see broad agreement with John’s talk. In terms of what to do below target, the softer language here allows room for John’s ‘maintenance carbs’ that he suggests (around 15g every 20 minutes). I should note here that my experience has been that, while I initially needed a protein bar before exercise to stave off lows, as my stamina/fitness improved, the need to do so has diminished. For example, the 10km/6 mile ride I did today I did without breakfast and no protein bar and stayed flat.

Dessi also suggests a backup glucose monitoring kit (good idea, especially for longer exercise intervals) and makes the excellent point that, as CGM can lag the true BGL value, a drop in BGL should be attended to as early possible.

Looping Settings For Exercise

John also had a table of pump settings (screenshot in my previous article) and Dessi’s are in broad agreement. As they are friendlier to read, I am including hers here (sorry John).

Dessi’s Summary and What Really Happens

This was her summary slide combining tips for loopers and non-loopers. Again, nothing too unusual here, compared to previous tips but all good information.

Of course, as she was going through all the suggestions I was thinking “yes, I will do that” and “no, I will not bother with that” and, as if she was reading my mind, she showed the slide above which aligned perfectly with my thinking.

Points 3-5 all relate to pre-exercise guidelines. I had dismissed these because, with a family, I cannot guarantee exactly when I will be starting exercise. For me it makes more sense to start following guidelines when I am about to ride, making points 1 and 2 the most relevant/practical.

Her conclusions align to what many of us with type 1 diabetes concluded long ago when it comes to managing our blood glucose levels: Academic guidelines are well and good, but everyone’s diabetes is different, and we need to work out what works for us.

Things to Take on the Ride

From my own riding adventures, these are the things I keep on me while riding. For storage, you can pick up very affordable bike storage bags/panniers on the usual sites (Amazon, eBay, etc.)

• A phone so you can monitor your CGM levels and/or a blood testing kit if you are not using a CGM. A phone can also be used to track your riding time and distance via apps like MapMyRide and Strava.
• Hypo snacks (long and short-acting) to treat hypos and stave them off during exercise. John had some excellent examples

• A medi-bracelet so, if there are issues, it can be quickly identified that you are a person with type 1 diabetes. Like the bike storage bags, these can be easily picked up online
• Sunscreen, especially if you are cycling in the sun
• Hydration: A riding bottle and bottle holder should be part of the bike or, you can also get wearable water bladders if you want to drink hands-free
• Appropriate clothing: Some bike shirts have zippable pockets for storage or otherwise, simply clothes which allow movement and you will not get too hot in. I have picked up some excellent bike clothing and accessories at second-hand clothing stores
• A smart watch: This is more a nice-to-have but I personally find it easier to check my BGLs on the watch by tapping it to my chin, than messing with the phone which is usually tracking the ride and not showing my BGLs

Bringing Together the Strategies for the Ride

Along with bringing the above along, here is the overall strategy summary for a morning bike ride, like those of the Blue Circle Cycling Club using my last post’s strategy as the foundation. Also note that, in the real world, people do not do all these things so work out which ones work for you.

Glucose Levels

• Non-Looping: 1-2 hours before, have a Low GI breakfast to raise glucose levels with a reduced bolus (around 25-50%) to minimise insulin on board AND/OR reduce basal rates (10-20% reduction) to allow blood glucose levels to rise to around 7-14mmol/L (126-152mg/dL)
• Looping: Skip breakfast, and 1-2 hours before set a higher loop target (around 8mmol/L = 144mg/dL) OR disable looping and follow the Non-Looping approach

During the Ride

• Monitor glucose levels and, if they are dropping, eat a snack to counteract the trend.
• If you already know how long you can exercise before levels start to drop, eat snacks accordingly. If unsure, start with eating around 15g of carbohydrate every 20 minutes of exercise.

After the Ride

• Have a snack/coffee post-ride, especially if you are driving home
• Monitor blood glucose levels for up to 24 hours
• Reduce bolus rates by 25-50% up to two hours are the ride
• Make any necessary adjustments to the approach for the following week.

Michelle Law has an excellent blog over at Pumps and Pricks. One thing she does is a ‘Top Ten’ of the conferences she attends. This year, like me, she attended EASD 2023, thanks to Dedoc, and posted her Top Ten Highlights. I have purposely not read it because this blog will do the same for EASD 2023 and ISPAD 2023. It will be interesting to see the areas of research that spoke to both of us and our different takes on them. The ranking of ten to one is not important; they are all interesting announcements/areas fo research.

10. Type 1 Diabetes Before Insulin

With drugs like Teplizumab which can delay the progression of type 1 diabetes, research is now focusing on the disease before the person becomes insulin dependent. These days there are four stages for type 1 diabetes with insulin only being needed in the third stage.

How do we know someone is likely to develop stage 3 type 1 diabetes? Because of the auto-antibodies in their blood which appear years before insulin is needed.

To shift this paradigm of type 1 diabetes being ‘insulin-dependent diabetes’, Kevan Herold described type 1 diabetes as an autoimmune disease with a metabolic outcome i.e. the beta cells stop working.

Flemming Pociot spoke of the limitations of just relying on auto-immune markers for early detection and how improved detection could be achieved by looking at genetic information and lipid profiles (FDR = First Degree Relative e.g. parent).

9. Time in Range is the New HbA1c

While there are plenty of people in the world without access to Continuous Glucose Monitors (CGMs), the people of Europe are generally not those people. So, it makes sense that the conferences focused a lot more on Time in Range (TIR) than on HbA1c.

Richard Bergenstal showed that, from a research perspective, TIR is as predictive as HbA1c

and provides a wealth of information an HbA1c measure does not, providing better guidance for the management plan for the disease.

Throughout the two conferences, as touched on below, many of the outcomes were focussed on Time in Rage, Time Above/Below range rather than HbA1c.

8. Exercise and Diabetes

There was a lot of talk about exercise at the conferences. Dessi Zaharieva spoke of the known benefits of exercise for people with diabetes.

and the barriers people with type 1 diabetes often face when considering exercise.

John Pemberton showed a post-meal walk can have a significant, positive impact on glucose levels.

Jennifer Leohr showed Lyumjev (URLi) worked better with exercise than Humalog (Lispro) inducing less hypos.

7. Looping/Automated Insulin Delivery (AID)

As we have seen in previous conferences, Looping systems (AID) showed superior performance to insulin pumps (IP) and multiple daily injections (MDI).

David Vavra showed similar results for HbA1c as well as other measures.

Javier Castaneda showed how 82% of those using the recommended settings on the commercial Minimed looping system achieve a Time in Tight Range (TITR) of over 50% which is, according to Thomas Danne, is sufficient to avoid long-term complications.

Comparing open-source looping systems to the commercial ones, Ludek Horvath found the open-source system yielded superior results but this could be a function of the people using them rather than any inherent advantage.

He also showed that looping systems achieve greater than 70% time in range which is significantly larger, and more consistent across countries, than the use of non-looping pumps or injections.

Katarina Braune also confirmed that open-source systems are at least as good as the commercial ones.

Yves Reznik talked about a study looking at people with type 2 diabetes, insulin dependent, but unable to give themselves injections. Moving to a looping system significantly improved their blood glucose levels.

At ISPAD, Roman Hovorka spoke of what is desirable in a looping system and confirmed “The right system is the one people are willing to use”.

There was also increased talk of ‘fully closed looping’ i.e. no manual bolusing or declaration of meals which I had not seen much of in previous conferences. Sarah Koning looked at how many grams of carbohydrate a loop can tolerate in a meal without announcements. The answer is somewhere between 0-60 and at least 20g. While meals of 61-80g led to less Time in Range (TIR) and Time Above Range (TAR) with fully closed looping, there was no increase in hypos or DKAs.

Lenka Drnkova (Petruzelkova) showed that a fully closed open-source loop performs as well as the same system with manual boluses or no-bolus meal declarations. There are still some kinks to work out though e.g. exercise.

6. A Psychologist as Part of the Diabetes Health Care Team

There was a lot of talk of a mental health specialist being part of the person with diabetes’ health care team. Agnieszka Szadkowska summed it up nicely in this slide where the psychologist is on equal footing with the rest of the therapeutic team.

Evelyn Cox presented preliminary findings linking mental health management with better clinical outcomes e.g. HbA1c and Time in Range.

Agata Chobot linked on-going psychological support for people with type 1 diabetes with improvement in severe hypoglycemia and DKA rates.

5. End Diabetes Stigma

The recognition of the end diabetes stigma campaign was throughout EASD 2023, starting out with the presidential address.

Jane Speight talked about those behind the campaign, how the pledge was created

and expanded on how many individuals and organisations had signed, and the reach of the campaign so far.

Richard I. G. Holt provided examples of how healthcare professional can be unwittingly part of the problem

and how stigma hinders optimal care.

4. Dual/Triple Agonists

Incretin Mimetics such as Ozempic/Wegovy have been big news for a while because, as well as being an excellent medication for type 2 diabetes, can result in weight loss. The next generation of these drugs are now coming to market and, while drugs like Ozempic target one type of receptor in the body, these new versions target 2 or more.

Jonathan Campbell talked about how dual agonists such as Tirzepatide work and, while they know what they do, how they do it is not as clear.

Hirenkumar Patel showed that, for people with type 2 diabetes, the use of Tirzepatide gave better results, both qualitatively and quantitatively, than basal insulin injections.

Eda Cengiz spoke of new research in a triple agonist which led to a 2% drop in HbA1c.

Merin Jose gave a word of warning that the rapid reduction in HbA1c resulting from these drugs can increase of the risk of diabetic retinopathy and this should be monitored closely.

3. Sleep and Diabetes

The benefits of sleep for people with diabetes came up during the conferences. Natalia Marhefkova showed how good sleep patterns directly affect outcomes e.g. a lower HbA1c. When asked by the audience what the ideal amount of sleep was, Natalia claimed it was 7-8 hours.

Erin Cobry also touched on the benefits of sleep for people with type 1 diabetes.

She also went on to talk about how Looping (AID) facilitates uninterrupted sleep and how even the interrupted sleep of carers can affect the clinical outcomes of the child they care for.

2. Diabetes and Diet

Jens Aberle talked about how if we plan to help manage the diet of people with diabetes, we need to better understand the reasons people are eating.

Emma Wilmot talked of a study which had confirmed that eating the carbohydrate foods last in a meal can have a significant impact on glucose peaks.

Hana Kahleova presented a study comparing a vegan diet to the ‘healthy plate’ and found while the healthy plate provided benefit in Hba1c and cholesterol, the vegan diet saw benefit in these and other measures such as daily insulin need, which was reduced, despite an increase in carbohydrate in-take.

Mark Clements talked about how smaller meals are easier to estimate for their carbohydrate content than larger ones

and how people with diabetes tend to underestimate the carbohydrate content of larger meals.

1. SGLT2is

This class of drugs lowers the threshold at which the body redirects blood glucose to the bladder. Aikaterini Eleftheriadou spoke of the benefits of SGLT2is compared to incretin mimetics in regard to long term complications.

Aino Latva-Rasku showed SGLT2is increase skeletal muscle and brain uptake in fatty acids in people with type 2 diabetes. One explanation is SGLT2is change the body’s preference for fuel source.

Milos Mraz spoke of the anti-inflammatory benefits for Type 1 Diabetes and while the blood glucose redirection mechanisms are understood, the other effects observed are not quite yet understood, similar to incretins.

Conclusions

My final thoughts (thanks Michelle) are:

(10) Type 1 Diabetes Before Insulin: The expansion of type 1 diabetes to consider the time ‘before insulin’ e.g. Stage 1 and 2 is really interesting. I wonder if this will lead to reclassification of LADA as simply a slow progressing form of Stage 2, Type 1 Diabetes.

The progress of early intervention type 1 drugs, such as Teplizumab, is really exciting and, hopefully will lead to a cure. One presentation spoke of using a combination of drugs whose effect for slowing progression will be additive and potentially ‘cure’ someone of type 1 diabetes, with the person taking pills rather than injections. While it has been promised for decades, with looping technology and immune system modifying drugs, we are genuinely getting closer to a practical cure.

(9) Time in Range is the New HbA1c: There is clearly an increased interest in using Time in Range (TIR) in academia, instead of the traditional HbA1c. My speculation as to “why?” is because it allows multiple secondary endpoints (additional measures) off of the same data whereas there is only so much you can do with an HbA1c measure. Unfortunately, bodies like the FDA who approve medications and diabetes technology still emphasize the value of HbA1c over TIR. This means for research to be useful to the manufacturers of the medications and technology, who also, in part, fund the research, HbA1c often needs to be the primary measure. Hopefully, in time, bodies like the FDA will see the value of TIR as a ‘primary endpoint’ in research.

(8) Exercise and Diabetes: There is increasing research into how to incorporate exercise into the lives of people with type 1 diabetes while allaying fears of hypoglycemia. This is great and can only be a good thing for diabetes management. For years I avoided exercise because of the concern of the effect it may have on short term blood glucose levels. Using the research, I am seeing at these conferences, I am now putting together a program for myself, and hopefully others with type 1 diabetes, which will help them introduce exercise into their lives safely.

(7) Looping/Automated Insulin Delivery (AID): Looping goes from strength to strength and there is a genuine belief in the looping research community that we are close to a fully closed loop. From my own experience I know of how looping reduces the burden of diabetes management significantly. While not a cure per se, looping makes mental room for other aspects of life and, for many, will bring precious relief from the constant harassment of management.

(6) A Psychologist as Part of the Diabetes Health Care Team: The rise in prominence of a psychologist on the health care team is well overdue and I look forward to this academic acknowledgement move to government policy and subsidised consults. While not disputed, the mental burden of diabetes management is rarely openly acknowledged. Access to psychological services, as a given for diabetes management, would be a huge step in this regard.

(5) End Diabetes Stigma: The rapid rise of the End Diabetes Stigma campaign is interesting. I have signed the petition and I hope it leads to something tangible for people with diabetes. People hide the fact they have diabetes and do not seek the help they need out of misplaced shame and embarrassment. This, in turn, leads to poor outcomes. In this sense ending diabetes stigma will save lives and improve the quality of life for many.

(4) Dual/Triple Agonists: This class of drugs is providing substantial benefit to people with diabetes, and I have spoken of these benefits in the past. In moving to double and triple agonists we are seeing an amplification of the effect and benefits and, while we do not completely understand the mechanisms in play, the promise of these drugs is significant.

(3) Sleep and Diabetes: For type 1 diabetes, interrupted sleep was often inevitable because of highs and lows, or because of split basal dosing. In the case of carers, the monitoring of the child with diabetes through the night also guaranteed broken sleep. Automated alarms and looping open the door for a complete night’s sleep for all. For myself, thanks to looping, a broken sleep because of diabetes may happen once a month but little more. Now I just need to work on getting the 7-8 hours sleep a night suggested to be optimal…

(2) Diabetes and Diet: While social media is awash in food hacks for people with diabetes, it is still good to have research-backed evidence on what is proven effective. Whether it is considering the psychological aspects of eating, or the practicality of estimating carbohydrates in a large meal, all of this informs people with diabetes on the best approach for them which has the best probability of success.

(1) SGLT2is: While there is still work to go on making these generally available for people with type 1 diabetes, due to factors such as the increased risk of DKA and eDKA, it is clear there are tremendous benefits in using them. I use a low dose SGLT2i at the moment, in combination with exercise once per week, and have seen a literally halving in my daily insulin needs and, without altering my diet, rarely see excursions beyond 8 mmol/L (144 mg/dL).

Thank you again to Dedoc for making it possible for me to attend these conferences and I strongly recommend, if you are an advocate who can #PayItForward to your community, applying for a Dedoc scholarship to attend a conference in 2024.

My first review was on Very Low Carbohydrate Diets (<50g carbohydrate/day) so if you are interested in ketogenic diets that is the literary (literature?) review for you. This review looks at academic papers researching Low Carbohydrate Diets (LCD, 50-130g carbohydrate/day). This is the area I generally aim for and, with looping, I have had success, bringing my HbA1c down to 5.6% i.e. within the non-diabetic reference range.

As before, I used PubMed and exactly the same search string as before. The difference was, in this case, I reviewed the 93 returned results, looking specifically for Low Carbohydrate Diets, not Very Low Carbohydrate Diets. As before, I only selected papers where the full publication was available and a quantitative group study of some kind was involved. The subjects also had to be human, not rodents etc.

Want to cut to the chase? Go straight to the tl;dr section at the end.

I plan to do a third review of plant-based diets for managing type 1 as well after this one. If there is a specific diet you would like me to trawl the literature for, let me know in the comments.

Brief Recap: Very Low Carbohydrate Diets (VLCDs)

In the previous review, there was no doubt that a VLCD can bring an average person’s HbA1c below 7% and, in some cases in the low 5% range. Whether going significantly below 7% was of benefit was not clear in the data provided by the search but, previously, I have shown that, if the occurrence of hypoglycemia can be controlled, getting below 6.4% will reduce the risk of long term complications.

To counter the clearly positive reduction in HbA1c, a few consequences/risks were also shown in the data which may need to be mitigated/monitored:

• “Oxidative stress” leading to possible organ damage and heart disease
• Glucagon response impairment
• Increased risk of eDKA (euglycemic diabetic ketoacidosis)

and the following table was also provided in one paper in regard to a ketogenic diet (KD).

As mentioned at the time, these aspects do not necessarily outweigh the benefits of a lower HbA1c and many of them can be monitored through regular checks and managed very effectively through the use of things like multivitamins, laxatives, and cholesterol medications.

The question I hope to address in this article is whether an LCD can provide a comparable benefit and whether it still incurs the same risks.

What HbA1c can we expect from an LCD?

For the VLCD, the HbA1c range from the studies was between 5.3% through to 6.8%. The best result I found for an LCD was 6.0% in “Low carbohydrate diet in type 1 diabetes, long-term improvement and adherence: A clinical audit”. This trial looked at 48 people with type 1 diabetes over four years. The average HbA1c change was from 7.6% down to 6.9% but strong ‘adherence’ to the <75g/day (participant decided exactly how much below this level) led to the 6.0% outcome.

Contrary to the VLCD results, this paper reported that cholesterol levels improved on this regimen. However, similar to what we saw in the VLCD diets, after 2 years, half had stopped adhering to the carbohydrate levels specified.

The study also suggested on-going education was vital to keep people on the plan and estimated the LCD was only applicable to about 20% of people with type 1 diabetes, presumably based on the drop-out rate.

The study with the highest HbA1c end point was “A randomised trial of the feasibility of a low carbohydrate diet vs standard carbohydrate counting in adults with type 1 diabetes taking body weight into account”. This study kept the carbohydrates to a strict 75g/day and went over 12 weeks with 10 people with type 1 diabetes. Insulin use went down (which I saw in other LCDs and VLCDs) and HbA1c went from 8.9% to 8.2%, which puts it on a level where the mortality rate is similar to the general population’s but well above the 7.0% and 6.4% targets mentioned earlier. There were no changes to the lipid profile over this time.

Other papers fell between these two extremes. In “A low carbohydrate diet in type 1 diabetes: clinical experience–a brief report”, 24 people with type 1 diabetes were given a diet with 70-90g of carbohydrate/day for 12 months and taught how to bolus for the meals. Hypoglycemia episodes went from around 3 per week to once per fortnight, their HbA1c went down from 7.5% to 6.4%, and cholesterol was mostly unchanged, except for an improvement in triglycerides.

One patient was reported with a final Hba1c of 4.7%, which is extraordinary and, given this is below even what the most dedicated VLCD folks got in the studies reviewed, I am not convinced this was representative of what can be achieved with an LCD.

One other paper reported an improved cholesterol profile on an LCD, specifically, “Changes in the lipidome in type 1 diabetes following low carbohydrate diet: Post‐hoc analysis of a randomized crossover trial”. In this study 10 adults with type 1 diabetes went through either an LCD of <100g of carbohydrates per day or a diet of >250g of carbohydrates per day over 12 weeks. In this case they reported “total cholesterol, LDL and triglycerides had not changed significantly in this trial and only HDL cholesterol was significantly elevated in the LCD arm”

In “The Impact of a Low-Carbohydrate Diet on Micronutrient Intake and Status in Adolescents with Type 1 Diabetes”, 20 adolescents with type 1 diabetes were given 50-80g of carbohydrate per day for 6 months. HbA1c averages went from 8.1% to 7.7%. Not a huge drop and, again, above our mentioned targets of 7% and 6.4%. The paper also recognised the issue of nutrition in adopting a reduced carbohydrate diet saying “The dietician should plan a diet enriched with foods containing soluble vitamins (in particular folate and thiamin), selenium, magnesium, calcium, and iron. Furthermore, we recommend supplementation in a specific quantity, such as yeast extract, Brazil nuts, and Wolffia globose daily. Finally, we advise checking vitamin and mineral blood levels every six months and, if necessary, supplementing daily intake with vitamins and minerals.”

Corroborating this was a paper mentioned in the VLCD review, “The Impact of a Low-Carbohydrate Diet on Micronutrient Intake and Status in Adolescents with Type 1 Diabetes”, which looked at the micronutrient impact of a diet with 50-80g of carbohydrate per day and concluded the diet had the risk of not being nutritionally complete. As suggested before, this could be easily mitigated with a multi-vitamin, supplements, and regular reviews.

Have There Been Studies Directly Comparing VLCDs and LCDs?

It could be argued that, while a list of risks have been identified in VLCDs, a lack of studies looking at these same factors in LCDs does not mean they are not applicable e.g. we do not know if there is an impaired glucagon response on an LCD. There have been some studies directly comparing VLCDs and LCDs to see where the differences are.

In “Low-Carbohydrate Diet among Children with Type 1 Diabetes: A Multi-Center Study”, carers of 624 children completed surveys about the carbohydrate intake of their children with type 1 diabetes. Of these, 36 were following an LCD, and, of these, 5 were following a VLCD. No significant differences were found in the HbA1c levels of the two groups but, again, the VLCD group showed abnormal lipid profiles, specifically, higher total cholesterol and lower HDLs.

In “Physical Activity, Dietary Patterns, and Glycemic Management in Active Individuals with Type 1 Diabetes: An Online Survey”, they deviated from the American Diabetes Association definitions we have been using so far and came up with their own,

• Normal (unrestricted): >200 g/day;
• Moderate: 100-200 g/day;
• Low-carbohydrate: 40–99 g/day;
• Very low-carbohydrate: <40 g/day.

The Low-carbohydrate and Very low-carbohydrate ranges are similar to our LCD and VLCD ranges so I have kept used these for broad comparison. In this case the survey was of 220 people with type 1 diabetes and, of these, around 41 were on a Low-carbohydrate diet and around 27 were on a Very low-carbohydrate diet. As with the previous study, there was no significant difference in HcA1c between participants engaging in Low and Very low-carbohydrate diets. However, of the diets, the Very low-carbohydrate diet was the most predicative of achieving an HbA1c below 7%.

tl;dr

In the literature, LCDs deliver a reduction in HbA1c to somewhere between 6.0% and 8.2%. This compares to around 5.3% to 6.8% for the VLCD. The spread within the range appears to relate to how strictly the diet is followed. In the original review, one paper suggested HbA1c increases by 0.1% for every additional 10g of carbohydrate consumed daily. If we assume a VLCD is roughly 40g/day and an LCD is 100g/day this predicts a range difference of 0.6%. While this roughly matches the results for the lower end i.e. “highly motivated individuals”, it is less predictive for the average participant.

In contrast to VLCDs, lipid profiles (cholesterol) either remained the same or improved under an LCD. However, like the VLCDs, there is a risk that micronutrient needs are not being met with the diet.

When studies directly compared VLCDs and LCDs, there was no significant difference in the achieved HbA1c but, on balance, the evidence suggests, a VLCD has the potential to result in a lower HbA1c than an LCD.

One study suggested on-going education/coaching was important for participants to stay with the diet and I think this applies equally to LCDs and VLCDs.

As we can see there is a mixed bag here. Depending on the HbA1c targets we are pursuing, our concern for our cholesterol levels, and the level of carbohydrate restriction we are willing to tolerate, one approach may be preferable to the other. As mentioned in the introduction I have found success which compares favourably to the VLCD studies with an LCD and technology (looping). I do not see the need to restrict my diet further but, if I saw my HbA1c beginning to rise, a VLCD would certainly be an option. To mitigate the risks of a VLCD/LCD diet I also take supplements and get myself checked to mitigate the risks identified for these kinds of diets e.g. vitamin levels checked regularly.

To this end, my conclusion is, probably unsurprisingly, to follow a similar approach to me. Determine the HbA1c you are looking to achieve and, if you are not achieving it, consider reducing carbohydrate intake as part of your management plan. Small changes can bring you easily into the LCD range and, with the risks identified in this and the previous review, steps put in place to manage them. If you achieve your goals you will, hopefully, have a sustainable plan. If you do not achieve your goals, you can always consider moving to a VLCD although, as identified above, building a supportive team around you to keep you on plan is key because of the high dropout rates for both LCDs and VLCDs.

As this is quite a long article, for those who prefer the destination than the journey, we have a tl;dr section at the end which summarises the findings.

For a review of Low Carbohydrate Diets (50-130g carbs/day) go here.

Questions covered in this review are:

• Does a VLCD lead to a lower HbA1c?
• Is the Lowest Possible HbA1c a Good Thing for Type 1 Diabetes?
• What are the Complications Associated With a VLCD?
• Does a VLCD Give Me All the Vitamins and Minerals I Need?
• Is a VLCD Sustainable?

Why Do a Review?

There are a lot of suggestions on social media about how to live well with type 1 diabetes. Some of them directly contradict each other. At one end of the dietary spectrum we have the ‘Mastering Diabetes‘ folks who promote a plant-based diet with minimal animal products, reducing insulin resistance (which even type 1s have) and, therefore, the amount of daily insulin required (bolus and basal).

At the other end of the spectrum, we have the folks like the Type 1 Gritters. They strictly follow the teachings of Doctor Richard Bernstein who promotes a very low carbohydrate diet (30g/day) with intense exercise to manage diabetes. The thinking here is that while insulin resistance may temporarily rise with the additional fats in the blood (possibly offset by the exercise), the sheer lack of carbohydrate in the diet means bolus insulin requirements are significantly reduced. Doctor Bernstein, who has lived with type 1 diabetes most of his life, has had tremendous success with his approach and is now coming up to 90 years old.

Doctor Bernstein documented his approach in a book called Dr. Bernstein’s Diabetes Solution. While excellent at describing the fundamentals of what type 1 diabetes is, unfortunately the book is now over ten years old and, in regard to technology, is quite out of date. The book dismisses continuous glucose monitors (although Dr. Bernstein now verbally supports them), insulin pumps, and flatly denies the existence of looping technology. For more contemporary wisdom from Dr. Bernstein, he has his YouTube channel, Dr. Bernstein’s Diabetes University. When I was first diagnosed, I watched practically every video on the channel and read the book (except the chapters on using insulin which, at the time, were not relevant to me). I took from it what made sense and parked the rest. It was an excellent foundation.

In the case of Dr. Bernstein, his diabetes management, informed by his health care team, was not working for him. Rather than be a passenger in his diabetes care, he started monitoring his blood glucose levels, determining what foods worked for him (low carb ones) and found a path which gave him success; the path he documented in his book so others could learn from his knowledge and experience. He ignored the zealots, did his own research, and adopted what worked for him. Every person with type 1 diabetes should be their own advocate, ignore the zealots, take control, determine the goals they wish to pursue, and find their path, just like Dr. Bernstein did.

Sadly, as if often the way with old texts, they are interpreted differently by different people. For me, the book was informative and gave me an approach to find my own diabetes management plan. It gave me permission to give critical thought to the advice of outsiders (including Dr. Bernstein) and make my own mind up. For others, like the Type 1 Gritters, it is a text which should be followed to the letter. I often bump my head against folk on Twitter who believe their goal (normal blood sugars) is the only goal which should be pursued and their approach (Dr. Bernstein’s Diabetes Solution) is the only approach to follow. Even when I have shown you can achieve superior results by embracing technology and NOT following Bernstein’s strict dietary plan, they continue with their dogmatism, the same kind of zealotry Dr. Bernstein fought all those years ago.

I am happy to give them the benefit of the doubt though as part of having critical thought is to listen to your detractors, consider their position and examine the evidence. This is what this article seeks to address. What evidence in the literature is there supporting a very low carbohydrate diet?

What is a Very Low Carbohydrate Diet?

In researching for this article I found academic literature, to allow for comparison, has broadly settled on the following definitions:

• Very Low Carbohydrate Diet (VLCD): <50g/day carbohydrate
• Low Carbohydrate Diet (LCD): 50-130g/day carbohydrate

Dr. Bernstein’s Diabetes Solution sits within the VLCD camp. I generally aim for LCD augmented with closed looping, which works for me in achieving my goals of having a sustainable/manageable approach and reducing my risk of long-term complications.

The Search Criteria

To find the articles, I used PubMed. PubMed is an online database for peer-reviewed medical articles and an excellent source for the latest research in diabetes. I try to review the latest findings once a month, collate questions, and discuss them with my endo when we meet.

My search was for the key phrases: “low carbohydrate” and “type 1 diabetes”. I had no interest in individual cases; if I wanted to hear about one person who got amazing results, I would go to Twitter and listen to the grifters selling their ‘services’. Group studies which show how the average person with type 1 achieves success with a VLCD was my target. I also wanted the full text of the paper to be available, so it could be debated openly, and a focus on quantitative information, not qualitative. The regimen being studied had to be VLCD with a focus on 30g or less/day diets, if available.

All up, the search returned a little over 90 papers. Where a paper made reference to another paper which could be of interest, I also followed the link and applied the same rules as above.

Does a VLCD lead to a lower HbA1c?

Yes it does! We have a few proof points of this. The first is “The glycaemic benefits of a very-low-carbohydrate ketogenic diet in adults with Type 1 diabetes mellitus may be opposed by increased hypoglycaemia risk and dyslipidaemia“. In this study 11 adults, who had been on a ketogenic diet (<55g/day) for an average of 2.6 years were studied and the following results found:

• Average HbA1c was 5.3%
• 0.9 hypoglycemia episodes per day
• “Total cholesterol, LDL cholesterol, total cholesterol/HDL cholesterol ratio, and triglycerides were above the recommended range in 82%, 82%, 64% and 27% of participants, respectively”

The second study which talked at the average HbA1c I have mentioned in previous blogs: “Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet“. This was a survey of the Type 1 Grit Facebook group. Of the 1,900 members of the group at the time, 316 responded with around half of these providing medical data. The following results were found:

• Average time following a VLCD: 2.2 years
• Average HbA1c was 5.67%
• Average daily carbohydrate intake was 36g/day
• 1 in 50 reported being hospitalised for hypoglycemia
• Noted a correlation between HbA1c and carbohydrate consumed i.e. an increase in HbA1c of 0.1% for every additional 10g of carbohydrate consumed daily
• Majority of respondents had dyslipidemia (abnormal cholesterol)

The two studies confirm that it is possible to get into the low 5% range with a VLCD. However, if someone is trying to convince you that a VLCD can consistently generate sub-5% HbA1c’s the odds are they are trying to sell you something because the evidence is simply not in PubMed.

There are two other commonalities between the studies. The first is dyslipidemia (abnormal cholesterol). If we believe these two studies are typical of VLCDs then it is reasonable to expect cholesterol results which will make your doctor frown. If cholesterol levels are important to you then a VLCD may work against you or will need to be managed.

The second commonality is the groups studied were not necessarily a random sample. In the case of the first paper, it is simply not stated where the participants came from; all we know is they were on a ketogenic diet for a number of years. In the case of the second, they came from a group dedicated to strictly following Dr. Bernstein’s approach. To join the group, participants have to pledge they follow Bernstein to the letter and have done for a “long period of time”. Here is an image of the application form to join the group.

Of those who make this commitment we have those who took the time to respond to the survey. In my mind this will also be a biased sample of those willing to share their success. It makes no sense to me that a group so committed to the cause would admit significant failure. Therefore, I see these results as the best an average person could hope for in adopting a VLCD, rather than an average or below-average measure.

A third study, “Safety and Efficacy of Eucaloric Very Low-Carb Diet (EVLCD) in Type 1 Diabetes: A One-Year Real-Life Retrospective Experience“v took 33 people with type 1 diabetes from an Italian clinic and switched them to a VLCD (<50g/day) for 12 months. Not surprisingly, in this case, the results were not as spectacular. The average HbA1c went from 8.3% at the start to 6.8% at the end.

Comparing to my own results, my HbA1c was last measured at 5.6%. This is better than the Type 1 Grit average without the need for a strict diet OR the exercise. However, for someone struggling to get their HbA1c below 7%, choosing a lower HbA1c as a goal to pursue, and indifferent to abnormal cholesterol levels, the VLCD may make sense.

Is the Lowest Possible HbA1c a Good Thing for Type 1 Diabetes?

Of the papers found through this process, some talked at the correlation between mortality rates and HbA1c. The first: “Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population” took a group of just over 1,400 people with type 1 diabetes and compared them to the general US population. They found that an HbA1c below 8.5% meant a lower mortality rate than the general population and, as can be seen on the graph below, below 7% the mortality rate was almost flat.

When the results were split by gender, a slightly different result emerged.

For males, while still quite flat, the mortality rate actually increased below 7% and started to be higher than the general population around 6%. This was not the case for women where an HbA1c continued to drop as the HbA1c went lower and become effectively unmeasurable at 6%.

Why would males have a higher mortality rate below an HbA1c of 7%? The speculation is the increase of hypos leads to an increased risk of death.

Backing up this surprising result was a second study: “Glycemic control and all-cause mortality risk in type 1 diabetes patients: the EURODIAB prospective complications study” Examining a little over 2,700 European people with type 1 diabetes it was found the all-cause mortality rate at an HbA1c of 11.8% and 5.6% was higher than at 8.1%.

The dotted lines are for a 95% confidence interval (think of these as error bars). Again, we see a crossover point with the general population between 8-9% and a more pronounced rising of mortality risk below 7%. In the discussion, the proposed reason for the increased mortality rate at lower HbA1cs was the increased risk of severe hypoglcemia.

Given the reference range for the HbA1c in a person without diabetes tops out at 5.6%, people with type 1 diabetes face a dilemma. If they chase normal blood sugars this means, on average, an increased risk of severe hypoglycemia and an increased risk of death. Thankfully, like many complications of diabetes, they are preventable if monitored closely. In the case of hypos, a continuous glucose monitor (CGM) would help keep track of lows before they become a problem. Similarly, a looping system would automatically intervene to prevent the hypo. It is possible, as these technologies become more widespread, the HbA1c to mortality rate curve will change allowing people with type 1 diabetes to safely pursue a normal range HbA1c without concerns of a hypo. Given the data behind these curves is over 30 years old, it is possible that modern insulins have already addressed the increased hypo risk and the curve, as HbA1c goes down, is flattened today. It will be good to get new data to confirm this is the case at some point.

What are the Complications Associated With a VLCD?

We mentioned the abnormal cholesterol results earlier but some papers did mention other complications as well. “Hyperketonemia and ketosis increase the risk of complications in type 1 diabetes” speaks at the health complications of a ketogenic diet (KD) which, arguably, a VLCD is. The main focus of the paper was “oxidative stress” leading to organ damage and heart disease but it also mentioned a raft of papers discussing other complications with a KD.

Again, how important these aspects are will depend on the individual and the goals they are pursuing. Also, some of these, such as constipation, can be addressed through medicinal interventions (laxatives).

Another paper, “Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study” sought to compare how a person responds to glucagon, based on whether they were on a VLCD (<50g/day) or a high carbohydrate diet (>250g/day). Presumably, due to the glycogen depletion in the liver, the response to glucagon in the VLCD cohort was impaired. Again, armed with this knowledge, a person pursuing a VLCD, who intends to use glucagon to manage severe hypos, can approach the situation prepared and perhaps change their plan to manage hypos with carbohydrates instead. Another consequence, mentioned in a few papers, was the risk of eDKA because of the significantly lower insulin requirements affecting basal control of the liver, and depleted glycogen stores.

Does a VLCD Give Me All the Vitamins and Minerals I Need?

Unless appropriately managed, the evidence suggests it does not. In “Prevalence of micronutrient deficiency in popular diet plans“, a VLCD, the “Atkins for Life” diet was examined in terms of its delivery of micronutrients (vitamins and minerals). It was significantly short in providing Vitamin B7 and Vitamin E.

Similarly, in “The Impact of a Low-Carbohydrate Diet on Micronutrient Intake and Status in Adolescents with Type 1 Diabetes” which considered a LCD of 50-80g/day it stated “LCD may result in nutritional deficiencies, as decreased carbohydrate consumption was positively correlated with decreases in vitamin and mineral intake that were not due to calorie reduction. Thus, these decreases resulted from the LCD content rather than from reduction in calories.”

This suggests that for both a VLCD and an LCD, a multivitamin may be needed to ensure micronutrient requirements are covered, with the possible consultation of a nutritionist.

Is a VLCD Sustainable?

I am sure there are individuals who have successfully maintained a VLCD for a very long time. However, if we are talking in general terms, the evidence is not strong that this is easy to do. Even in the Type 1 Grit study, after an average of 2.2 years, the majority of the participants were failing to meet the Bernstein guideline of no more than 30g/day of carbohydrate. Other studies also believed a VLCD had troubles being maintained. “Low-Carb and Ketogenic Diets in Type 1 and Type 2 Diabetes” states “An issue about the use of LCD (less than 100g/day) can be the long-term tolerability. In many cases LCD was stopped before 1–2 years for a variety of reasons, often because intolerable and with a limited choice of foods” and “A clinical audit performed to assess the long-term adherence to LCD in people with T1D showed that after two years about half of the people ceased adhering…”

Even in our HbA1c studies at the start of this review the average time spent on a VLCD was no more than three years. This suggests if a person’s plan is to adopt a VLCD beyond a couple of years, they will need to ensure it is aligned to their lifestyle and has sufficient variety of food to keep it interesting. The food variety may also help address the nutritional deficiencies mentioned earlier.

tl;dr

Given the claims often made about very low carbohydrate diets (VLCDs) and the contradictory messaging about the best way to live with type 1 diabetes, it is worth examining the available evidence to see what an average person with type 1 diabetes can expect. To do this a review of the PubMed literature was performed.

While there is no doubt that a VLCD can reduce the HbA1c of a person with type 1 diabetes to below 7%, there is a need to manage the resulting risks/complications. If the person adopting the diet is experiencing an increase in hypos, these will need to be managed, mindful that glucagon is often not as effective for people on a VLCD. Cholesterol levels are often out of the recommended ranges on a VLCD and this should be managed, ideally in consultation with the person’s health care team. If it is a concern then, in the case of LDL, cholesterol-lowering medications may be recommended. Other complications, such as constipation, diarrhea, kidney stones and the more serious organ damage and heart disease, should also be monitored for and, if they arise, addressed through other interventions e.g. medication and/or diet. To ensure the diet being adhered to is nutritionally complete, either a multivitamin should be taken and/or the advice of a nutritionist should be sought. Finally, the shift to a VLCD will be, for most people a significant change in lifestyle. With many people not sticking with a VLCD beyond 2-3 years, steps should be taken to make the diet both interesting (a variety of food) and practical for one’s life to maximise the chances of success.

Based on the above evidence, I can see why healthcare professionals are often cautious to recommend a VLCD for their clients as the picture painted above is not completely glowing and, given I am already achieving better management of type 1 diabetes without adopting a VLCD, I will stick to what works for me. My next step will be to assess the literature for an LCD (50-130g/day) to see if this can achieve similar results without the severity of impact or the same complications.